We evaluated the association between estimated glomerular filtration rate (eGFR) and slow coronary flow (SCF) in patients with normal to mildly impaired renal function; 211 patients with angiographically proven SCF and 219 controls were studied. Patients were categorized based on the angiographic findings as with or without SCF. We used the Modification of Diet in Renal Disease equation to calculate eGFR. The frequency of mildly decreased eGFR, serum uric acid levels, and eGFR was higher in the SCF group. Patients with mildly impaired renal function had higher thrombolysis in myocardial infarction frame counts in 3 major coronary arteries. In logistic regression analysis, uric acid (odds ratio [OR] = 1.323, 95% confidence interval [CI] = 1.109-1.572, P = .002) and eGFR (OR = 0.972, 95% CI = 0.957-0.987, P < .001) were independent correlates of SCF. In conclusion, eGFR was significantly correlated with SCF in patients with normal to mildly impaired renal function.
TambeAADemanyMAZimmermanHAMascarenhasE. Angina pectoris and slow flow velocity of dye in coronary arteries: a new angiographic finding. Am Heart J. 1972;84(1):66–71.
2.
GoelPKGuptaSKAgarwalAKapoorA. Slow coronary flow: a distinct angiographic subgroup in syndrome X. Angiology. 2001;52(8):507–514.
3.
MangieriEMacchiarelliGCiavolellaM. Slow coronary flow: clinical and histopathological features in patients with otherwise normal epicardial coronary arteries. Cathet Cardiovasc Diagn. 1996;37(4):375–381.
4.
MosseriMYaromRGotsmanMSHasinY. Histologic evidence for small-vessel coronary artery disease in patients with angina pectoris and patent large coronary arteries. Circulation. 1986;74(5):964–972.
5.
PekdemirHCinVGCicekD. Slow coronary flow may be a sign of diffuse atherosclerosis. Contribution of FFR and IVUS. Acta Cardiol. 2004;59(2):127–133.
6.
TurhanHSaydamGSErbayAR. Increased plasma soluble adhesion molecules: ICAM-1, VCAM-1, and E-selectin levels in patients with slow coronary flow. Int J Cardiol. 2005;98(2):450–456.
7.
SezginATBarutcuISezginN. Contribution of plasma lipid disturbances to vascular endothelial function in patients with slow coronary flow. Angiology. 2006-2007;57(6):694–701.
8.
GokceMKaplanSTekeliogluYErdoganTKucukosmanogluM. Platelet function disorder in patients with coronary slow flow. Clin Cardiol. 2005;28(3):145–148.
9.
AmasyaliBTurhanHKoseS. Aborted sudden cardiac death in a 20-year-old man with slow coronary flow. Int J Cardiol. 2006;109(3):427–429.
10.
MuntnerPHeJHammLLoriaCWheltonPK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002;13(3):745–753.
11.
CulletonBFLarsonMGWilsonPWEvansJCParfreyPSLevyD. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999;56(6):2214–2219.
12.
ShlipakMGSimonJAGradyD. Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. J Am Coll Cardiol. 2001;38(3):705–711.
13.
YilmazMBYaltaK. Coronary flow slows as renal function worsens. Clin Cardiol. 2009;32(5):278–282.
14.
SobkowiczBTomaszuk-KazberukAKraliszP. Coronary blood flow in patients with end-stage renal disease assessed by thrombolysis in myocardial infarction frame count method. Nephrol Dial Transplant. 2010;25(3):926–930.
15.
LeveyASGreeneTKusekJW. A simplified equation to predict glomerular filtration rate from serum creatinine [abstract]. J Am Soc Nephrol. 2000;11:A0828.
16.
GibsonCMCannonCPDaleyWL. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93(5):879–888.
17.
LücherTFRichardVTschudiMYangZHBoulangerC. Endothelial control of vascular tone in large and small coronary arteries. J Am Coll Cardiol. 1990;15(3):512–527.
18.
SezginNBarutcuISezginAT. Plasma nitric oxide level and its role in slow coronary flow phenomenon. Int Heart J. 2005;46(3):373–382.
19.
SelcukHSelcukMTTemizhanA. Decreased plasma concentrations of adiponectin in patients with slow coronary flow. Heart Vessels. 2009;24(1):1–7
20.
YildizAGurMYilmazR. Association of paraoxonase activity and coronary blood flow. Atherosclerosis. 2008;197(1):257–263.
21.
ZoccaliCBode-BogerSMallamaciF. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001;358(9299):2113–2117.
22.
KielsteinJTBogerRHBode-BogerSM. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol. 1999;10(3):594–600.
23.
ReffelmannTKrebsAIttermannT. Mild renal dysfunction as a non-traditional cardiovascular risk factor? Association of cystatin C-based glomerular filtration rate with flow-mediated vasodilation. Atherosclerosis. 2010;211(2):660–666.
24.
PerticoneFMaioRTripepiGZoccaliC. Endothelial dysfunction and mild renal insufficiency in essential hypertension. Circulation. 2004;110(7):821–825.
25.
ZhangLGongDLiSZhouX. Meta-analysis of the effects of statin therapy on endothelial function in patients with diabetes mellitus. Atherosclerosis. 2012;223(1):78–85.
26.
RerianiMKDunlaySMGuptaB. Effects of statins on coronary and peripheral endothelial function in humans: a systematic review and meta-analysis of randomized controlled trials. Eur J Cardiovasc Prev Rehabil. 2011;18(5):704–716.
27.
NikolicDBanachMNikfarS. Lipid and blood pressure meta-analysis collaboration group. A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?Int J Cardiol. 2013;168(6):5437–5447.
28.
ErdoganDCaliskanMGulluHSezginATYildirirAMuderrisogluH. Coronary flow reserve is impaired in patients with slow coronary flow. Atherosclerosis. 2007;191(1):168–174.
29.
RadgostaMSamadyHRossIGimpleLWSarembockIJPowersER. Coronary flow reserve abnormalities in patients with diabetes mellitus who have end-stage renal disease and normal epicardial coronary arteries. Am Heart J. 2004;147(6):1017–1023.
30.
SobkowiczBTomaszuk-KazberukAKraliszP. Value of the real-time myocardial contrast echocardiography for risk stratification and for the detection of significant coronary stenosis in patients with end-stage renal disease. Nephrol Dial Transplant. 2007;22(2):668–669.
31.
ChadeARBroshDHiganoSTLennonRJLermanLOLermanA. Mild renal insufficiency is associated with reduced coronary flow in patients with non-obstructive coronary artery disease. Kidney Int. 2006;69(2):266–271.
32.
KanbayMSánchez-LozadaLGFrancoM. Microvascular disease and its role in the brain and cardiovascular system: a potential role for uric acid as a cardiorenal toxin. Nephrol Dial Transplant. 2011;26(2):430–437.
33.
CorryDBEslamiPYamamotoKNybyMDMakinoHTuckML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin–angiotensin system. J Hypertens. 2008;26(2):269–275.
34.
GulluHErdoganDCaliskanM. Elevated serum uric acid levels impair coronary microvascular function in patients with idiopathic dilated cardiomyopathy. Eur J Heart Fail. 2007;9(5):466–468.
35.
DaskalopoulouSSTzovarasVMikhailidisDPElisafM. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr Pharm Des. 2005;11(32):4161–475.
36.
TakagiHUmemotoT. Atorvastatin therapy reduces serum uric acid levels: a meta-analysis of randomized controlled trials. Int J Cardiol. 2012;157(2):255–257.
37.
AthyrosVGElisafMPapageorgiouAA. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis. 2004;43(4):589–599.
38.
CinVGPekdemirHCamsarA. Diffuse intimal thickening of coronary arteries in slow coronary flow. Jpn Heart J. 2003;44(6):907–919.
39.
AbaciAOguzhanAEryolNKErginA. Effect of potential confounding factors on the thrombolysis in myocardial infarction trial frame count and its reproducibility. Circulation. 1999;100(22):2219–2223.
